Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Schering-Plough
α= 0.05. α's Z=1.96 β= 80%. β's Z=0.84 Estimated proportion of subjects to achieve optimal control of arterial hypertension= 83.2%
450 subjects are expected to be enrolled in the study of which 40 subjects will be enrolled in Venezuela.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women 18 years of age or older
Essential arterial hypertension Stade I and II according to JNC VII
Signature of Informed Consent
You may not be if
Secondary arterial hypertension
Pregnant woman or during lactancy
Recent cardiovascular disease, as heart attack, unstable angina, or procedures of coronary revascularization on the previous six months.
Acute Coronary Failure Syndrome on the previous six months.
Chronic Ischemic Cardiopathy Treatment.
Cerebral Vascular Disease on the previous six months.
Alcoholism Story or use of drugs on the two previous years.
Hepatic Disease Story
Chronic Renal Failure defined by a serumal creatinine higher than 2mg/dl
Albuminuria higher than 1gr.
Known Allergy to blockers of angiotensine II receptors.
Neoplasmic Malignant Disease included leukemia and the lymphoma (Skin basocellular cancer is not included)
Auto Immune Disorders as systemic erythematosus lupus.
Non attachment to medical treatments history.
Patients sharing some clinical investigation essay on the last 3 months.
Congestive heart failure under previous treatment with ECA inhibitors.
Allergy to thiazidic diuretics.
Angioedema History
Use of drugs that affect potassium secretion, as diuretic savers of potassium, angiotensine enzyme inhibitor, betablockers, non-steroid anti-inflammatory drugs.
Potassium consumption orally
Clareo Health | Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)
